NEWS
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Pyxis Oncology (NASDAQ: PYXS) announced positive preliminary data from its Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate targeting Extradomain-B Fibronectin. The drug achieved a 50% objective response rate including one complete response in head and neck cancer patients, and 26% overall response rate across six solid tumor types. PYX-201 demonstrated a favorable safety profile and dose-dependent responses. The company also announced a new clinical trial collaboration with Merck to evaluate PYX-201 in combination with KEYTRUDA®, with dosing expected to begin in Q1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2655Followers
107Following
29KVisitors
Follow
Northern Lights : I'm curious. Is it typical for the price to drop with pharmaceutical stocks to drop on good pr?
Jaguar8 OP Northern Lights : It’s shorts
Northern Lights Jaguar8 OP : Gotcha, thank you. BTW, I really enjoy your insights and call outs. Thanks again!
Jaguar8 OP Northern Lights : Thank you!